AnorMED Inc.

PROFILE AnorMED might have the mettle, and the "metal", to cure life-threatening diseases. The company is developing therapeutic and diagnostic products that utilize metal complexes and metal-binding compounds. In its pipeline are a platinum-based anticancer drug licensed to AstraZeneca and a technetium-based imaging product licensed to DuPont Pharmaceuticals. Lambda, a phosphate-binding agent for dialysis patients being developed with Shire Pharmaceuticals, is in Phase III trials in Europe. Other products include drugs for autoimmune disorders and HIV. AnorMED hopes to find partners for these products when they're ready to market as well.  COMPETITION AEterna Laboratories Inc. (AELA) Agouron Pharmaceuticals, Inc. (dossier) IDEC Pharmaceuticals Corporation (IDPH)		FINANCIAL OVERVIEW Fiscal Year-End: March 2000 Sales (mil.): 1.90 1-Yr. Sales Growth: (73.0)% Employees: 67 Revenue per employee: $28,358.21  KEY PEOPLE • Michael J. Abrams     CEO • W. J. Adams     CFO  CONTACT INFO Ste. 200, 20353 64th Ave. Langley British Columbia V2Y 1N5, Canada Phone: 1-604-530-1057 Fax: 1-604-530-0976 Online: Web Site

	Company Data   News, quotes & more

		Hoover's Company Capsule Copyright © 2001, Hoover's Inc. Austin, Texas. For changes and updates, contact Hoover's directly.